Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03610633 · ClinicalTrials.gov registry record · Phase 2

Oxytocin and Stress Response in Alcohol Use Disorder

A Phase 2 study of Alcohol Use Disorder, sponsored by Medical University of South Carolina.

Completed
Registry status
Phase 2
Development phase
11
Enrollment target
1
Study location

NCT03610633 is a Phase 2 study of Alcohol Use Disorder that has completed, run by Medical University of South Carolina. The registered enrollment target is 11 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03610633, a Phase 2 study of Alcohol Use Disorder, has completed, sponsored by Medical University of South Carolina.

COMPLETED
Registry status
Phase 2
Development phase
11 participants
Enrollment target
1
Study location

Study Summary

Individuals with alcohol use disorder (AUD) will complete one functional Magnetic Resonance Imaging (fMRI) scanning visit. Prior to the scan, individuals will receive a nasal spray of either 24 international units (IU) of oxytocin (OT), or placebo (PBO). During the scan, they will perform the Montreal Imaging Stress Task (MIST), a social stress task. Subjective craving and anxiety data will be collected.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Oxytocin

Study Locations (1)

South Carolina

  • Addiction Sciences Division-Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2016-03
Est. Completion 2018-09
Phase Phase 2

What the Registry Record Tells You About NCT03610633

The ClinicalTrials.gov registry entry for NCT03610633 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (97% lower). The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03610633 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.

Frequently Asked Questions

What is clinical trial NCT03610633 about?

NCT03610633 is a clinical study titled "Oxytocin and Stress Response in Alcohol Use Disorder". Individuals with alcohol use disorder (AUD) will complete one functional Magnetic Resonance Imaging (fMRI) scanning visit. Prior to the scan, individuals will receive a nasal spray of either 24 international units (IU) of oxytocin (OT), or placebo (PBO). During the scan, they will perform the Montre...

What is the current status of trial NCT03610633?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2016-03. Estimated completion is 2018-09.

What conditions does trial NCT03610633 study?

This clinical trial studies the following conditions: Alcohol Use Disorder.

What interventions are being tested in trial NCT03610633?

The interventions under investigation include: Placebo (DRUG), Oxytocin (DRUG).

Who is sponsoring clinical trial NCT03610633?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03610633 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcohol Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.